CalciMedica, Inc. (CALC) stock
CALCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$1.22+0.03 (+2.52%)
Close on Nov 17, 2026Market cap $41.65MP/E –Yield –
CalciMedica EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
CalciMedica's EPS for the twelve months ending Jun 30, 2026 was -$1.35. For fiscal 2025 it was -$1.97. The highest annual figure on record is -$1.22 in fiscal 2024.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.97 | – |
| FY2024 | Dec 31, 2024 | -$1.22 | – |
| FY2023 | Dec 31, 2023 | -$7.66 | – |
| FY2022 | Dec 31, 2022 | -$111.16 | – |
| FY2021 | Dec 31, 2021 | -$1.69 | – |
| FY2020 | Dec 31, 2020 | -$5.25 | – |
| FY2019 | Dec 31, 2019 | -$33.41 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.45 | – |
| Q1 FY2026 | Mar 31, 2026 | $0.30 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.68 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.52 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.40 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.36 | -3700.0% |
| Q4 FY2024 | Dec 31, 2024 | -$0.33 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.50 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.36 | – |
| Q1 FY2024 | Mar 31, 2024 | $0.01 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.82 | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.11 | – |
| Q1 FY2023 | Mar 31, 2023 | -$23.43 | – |
| Q2 FY2022 | Jun 30, 2022 | -$36.55 | – |
| Q1 FY2022 | Mar 31, 2022 | -$46.13 | – |
| Q4 FY2021 | Dec 31, 2021 | -$0.41 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.38 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.36 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.54 | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.52 | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.79 | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.61 | – |
| Q4 FY2019 | Dec 31, 2019 | -$9.26 | – |
| Q3 FY2019 | Sep 30, 2019 | -$9.30 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?